Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R D Weeratna

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Current Drug Targets. Infectious Disorders|November 29, 2002
Novel adjuvant systemsM J McCluskie, R D Weeratna
Applied and Environmental Microbiology|October 1, 1991
Detection and production of verotoxin 1 of Escherichia coli O157:H7 in foodR D Weeratna, M P Doyle
Vaccine|March 21, 2001
The potential of oligodeoxynucleotides as mucosal and parenteral adjuvantsM J McCluskie, R D Weeratna, H L Davis
Springer Seminars in Immunopathology|August 17, 2000
The role of CpG in DNA vaccinesM J McCluskie, R D Weeratna, H L Davis
Molecular Medicine (Cambridge, Mass.)|December 29, 2000
Intranasal immunization of mice with CpG DNA induces strong systemic and mucosal responses that are influenced by other mucosal adjuvants and antigen distributionM J McCluskie, R D Weeratna, H L Davis
Vaccine|March 4, 2000
CpG DNA induces stronger immune responses with less toxicity than other adjuvantsR D Weeratna, M J McCluskie, Y Xu, et al.
Vaccine|December 15, 2000
CpG DNA is an effective oral adjuvant to protein antigens in miceM J McCluskie, R D Weeratna, A M Krieg, et al.
Gene Therapy|September 26, 2001
Immune-mediated destruction of transfected myocytes following DNA vaccination occurs via multiple mechanismsP J Payette, R D Weeratna, M J McCluskie, et al.
Current Opinion in Investigational Drugs (London, England : 2000)|August 31, 2001
The use of CpG DNA as a mucosal vaccine adjuvantM J McCluskie, R D Weeratna, P J Payette, et al.
Vaccine|June 8, 2001
Mucosal immunization of mice using CpG DNA and/or mutants of the heat-labile enterotoxin of Escherichia coli as adjuvantsM J McCluskie, R D Weeratna, J D Clements, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Current Drug Targets. Infectious Disorders|November 29, 2002
Novel adjuvant systemsM J McCluskie, R D Weeratna
Applied and Environmental Microbiology|October 1, 1991
Detection and production of verotoxin 1 of Escherichia coli O157:H7 in foodR D Weeratna, M P Doyle
Vaccine|March 21, 2001
The potential of oligodeoxynucleotides as mucosal and parenteral adjuvantsM J McCluskie, R D Weeratna, H L Davis
Springer Seminars in Immunopathology|August 17, 2000
The role of CpG in DNA vaccinesM J McCluskie, R D Weeratna, H L Davis
Molecular Medicine (Cambridge, Mass.)|December 29, 2000
Intranasal immunization of mice with CpG DNA induces strong systemic and mucosal responses that are influenced by other mucosal adjuvants and antigen distributionM J McCluskie, R D Weeratna, H L Davis
Vaccine|March 4, 2000
CpG DNA induces stronger immune responses with less toxicity than other adjuvantsR D Weeratna, M J McCluskie, Y Xu, et al.
Vaccine|December 15, 2000
CpG DNA is an effective oral adjuvant to protein antigens in miceM J McCluskie, R D Weeratna, A M Krieg, et al.
Gene Therapy|September 26, 2001
Immune-mediated destruction of transfected myocytes following DNA vaccination occurs via multiple mechanismsP J Payette, R D Weeratna, M J McCluskie, et al.
Current Opinion in Investigational Drugs (London, England : 2000)|August 31, 2001
The use of CpG DNA as a mucosal vaccine adjuvantM J McCluskie, R D Weeratna, P J Payette, et al.
Vaccine|June 8, 2001
Mucosal immunization of mice using CpG DNA and/or mutants of the heat-labile enterotoxin of Escherichia coli as adjuvantsM J McCluskie, R D Weeratna, J D Clements, et al.
Pageof 2